Connection
Brian Freed to Retrospective Studies
This is a "connection" page, showing publications Brian Freed has written about Retrospective Studies.
|
|
Connection Strength |
|
|
|
|
|
0.121 |
|
|
|
-
Roark CL, Ho BE, Aubrey MT, Anobile C, Israeli S, Phang TL, Braxton D, Ho AP, Freed BM. HLA homozygosity is associated with Non-Hodgkin lymphoma. Hum Immunol. 2022 Oct; 83(10):730-735.
Score: 0.066
-
Solomon SR, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, Jackson KC, Morris LE, Holland HK, Solh MM, Bashey A. Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables. Biol Blood Marrow Transplant. 2018 04; 24(4):789-798.
Score: 0.012
-
Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 04; 18(4):907-915.
Score: 0.012
-
Adebiyi OO, Gralla J, Klem P, Freed B, Davis S, Wiseman AC, Cooper JE. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients. Am J Transplant. 2016 12; 16(12):3458-3467.
Score: 0.011
-
Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012 Aug; 18(8):1265-72.
Score: 0.008
-
Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant. 2006 Sep; 21(9):2625-9.
Score: 0.005
-
Isenberg A, Singh TP, Shen GK, Freed BM, Conti DJ. Selective CellCept therapy in high-risk renal transplant recipients. Transplant Proc. 1998 Jun; 30(4):1188-9.
Score: 0.003
-
Conti DJ, Freed BM, Gruber SA, Singh TP, Gallichio M, Lempert N. Impact of retransplant status on delayed graft function: an analysis of paired cadaver kidneys. Transplant Proc. 1995 Feb; 27(1):1070-1.
Score: 0.002
-
Conti DJ, Freed BM, Lempert N. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant Proc. 1993 Feb; 25(1 Pt 2):1421-2.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|